newsfilter
← Latest News
GlobeNewswire·

Calithera Biosciences to Present First Clinical Data from Development Program for Arginase Inhibitor CB-280 at NACFC 2021

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage biopharmaceutical company, today announced that data from its Phase 1b trial of CB-280, the company's investigational arginase in